C12N 2760/18451
Methods of production or purification of viral material
C12N2760/18451 (Methods of production or purification of viral material) appears on 32 US grants and 42 published applications in this corpus.
Search patents in C12N- Granted patents
- 32
- Published applications
- 42
- Assignees
- 33
- Inventors
- 87
- Latest grant
- 10 Dec 2024
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1978 | 1 | 0 |
| 1979 | 1 | 0 |
| 1980 | 0 | 0 |
| 1981 | 0 | 0 |
| 1982 | 1 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 0 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 1 | 3 |
| 2002 | 3 | 0 |
| 2003 | 2 | 1 |
| 2004 | 1 | 0 |
| 2005 | 0 | 1 |
| 2006 | 0 | 2 |
| 2007 | 0 | 1 |
| 2008 | 0 | 3 |
| 2009 | 0 | 0 |
| 2010 | 1 | 2 |
| 2011 | 2 | 3 |
| 2012 | 0 | 0 |
| 2013 | 0 | 1 |
| 2014 | 0 | 2 |
| 2015 | 2 | 1 |
| 2016 | 2 | 4 |
| 2017 | 2 | 1 |
| 2018 | 2 | 4 |
| 2019 | 2 | 1 |
| 2020 | 4 | 4 |
| 2021 | 1 | 3 |
| 2022 | 1 | 0 |
| 2023 | 1 | 0 |
| 2024 | 2 | 3 |
| 2025 | 0 | 1 |
| 2026 | 0 | 1 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Recombinant measles viruses expressing epitopes of antigens of RNA viruses—use for the preparation of vaccine compositions10 Dec 2024US 12,163,150 B2Centre National De La Recherche Scientifique
- Lassa vaccine7 May 2024US 11,976,305 B2Centre National De La Recherche Scientifique
- Aseptic purification process for viruses18 Apr 2023US 11,629,339 B2Valneva SE
- Method for producing self-assembling paramyxoviral nucleocapsid-like particles and their uses3 May 2022US 11,319,350 B2Centre National De La Recherche Scientifique
- Intranasal vector vaccine against porcine epidemic diarrhea2 Feb 2021US 10,905,758 B2
- Method of producing negative-strand rna virus vector and produced negative-strand rna virus vector27 Aug 2026US 2026/0250709 A1Repli-Tech Co., Ltd.
- Reverse genetics system for feline morbillivirus2 Oct 2025US 2025/0304921 A1University of Pittsburgh—Of the Commonwealth System of Higher Education
- Method of producing negative-strand rna virus vector and produced negative-strand rna virus vector19 Sep 2024US 2024/0309335 A1Repli-Tech Co., Ltd.
- Recombinant measles virus5 Sep 2024US 2024/0293533 A1
- Methods and compositions for detecting and producing porcine morbillivirus and vaccines thereof2 May 2024US 2024/0139306 A1Iowa State University Research Foundation, Inc.
Most cited
By later US patents
- Production of viruses in tissue culture without use of serum39US 4,072,565 AThe Dow Chemical Company · 1978
- Vaccine stabilizer containing L-glutamic acid and L-arginine36US 4,338,335 AMerck & Co., Inc. · 1982
- Method for the preservation of viruses and mycoplasma35US 6,664,099 B1Anhydro Limited · 2003
- Stabilizers for live vaccines25US 6,231,860 B1Pasteur Merieux Serums & Vaccins · 2001
- Vaccine stabilizer22US 4,147,772 AMerck & Co., Inc. · 1979